Home/TechImmune/Chris Dedic

CD

Chris Dedic

Chief Financial Officer

Therapeutic Areas

Infectious Disease Long COVID

TechImmune Pipeline

Drug	Indication	Phase
Long COVID Immunotherapy	Treatment of Long COVID / Post-Acute Sequelae of SARS-CoV-2 (PASC)	Pre-clinical
Acute COVID-19 Antiviral Therapy	Treatment of acute COVID-19, prevention of Long COVID	Pre-clinical

Leadership Team at TechImmune

James F. Young, PhD

Executive Chairman

Jeffrey Ulmer, PhD

Chief Executive Officer and Board Member

Lbachir BenMohamed, PhD

Vice President and Board Member

Chief Operating Officer and Board Member

View full TechImmune profile